Bone Therapeutics provides Third Quarter 2022 Business Update
globenewswire.com
news
2022-10-21 00:00:00

English French REGULATED INFORMATION Mont-Saint-Guibert, Belgium, 21 October 2022, 7am CEST â€“ BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update for the third quarter, ended 30 September 2022. 'If approved by its shareholders, Bone Therapeutics' acquisition of Medsenic majority participation will combine the allogeneic cell therapy product, ALLOB with Medsenic's dedicated best-in-class autoimmune disease platform as well as the respective teams, intellectual property and know-how.
